Epistem offers a range of in vitro options for assessment of preclinical novel therapeutic agents including target expression, pathway analysis and cytotoxicity assays. Cancer stem cell and angiogenesis assays provide more in-depth readouts of efficacy.
The first step in assessing efficacy must be selection of the appropriate models. Epistem can assist in the selection of appropriate cell lines and tumour types by evaluating target expression levels. Target expression can be quantified by immunohistochemistry with image analysis or by gene expression profiling. Epistem's proprietary gene expression technology enables analysis of very small amounts of starting material, whether cultured cells or areas isolated from diseased tissue by laser capture microdissection.